Gilead Sciences Backs 2009 Sales View $5.9 Billion-$6 Billion
2009年3月17日 - 3:45AM
Dow Jones News
Gilead Sciences Inc. (GILD) continues to expect full-year 2009
sales of $5.9 billion to $6 billion, reiterating a projection first
provided in January.
Many analysts have viewed that guidance as conservative and the
mean Wall Street estimate is currently $6.27 billion, according to
Thomson Reuters.
The Foster City, Calif., drug maker's chief executive, John
Martin, speaking at a Cowen & Co. health care conference in
Boston, noted that the company will adjust its guidance after
completing its planned $1.4 billion acquisition of CV Therapeutics
Inc. (CVTX).
Gilead projects the deal to be dilutive to earnings in 2009,
neutral to accretive in 2010 and accretive in 2011 and beyond.
The company, primarily known for its presence in selling HIV
treatments, reported 2008 sales of $5.08 billion, a rise of 36%
from a year earlier.
Shares of Gilead recently traded down 84 cents, or 1.9%, to
$44.58.
-By Thomas Gryta, Dow Jones Newswires; 201-938-2053;
thomas.gryta@dowjones.com